937602-51-2 Usage
Molecular Weight
400.26 g/mol
Functional Groups
tert-butyl group (C4H9)
ethyl group (C2H5)
bromo-substituted indole ring
two carboxylate groups (COO-)
Structure
The indole ring is fused with a six-membered ring, containing a nitrogen atom.
The tert-butyl group is attached to the first position of the indole ring.
The ethyl group is attached to the second position of the indole ring.
The bromine atom is attached to the fifth position of the indole ring.
The carboxylate groups are attached to the first and second positions of the indole ring.
Applications
Building block in organic synthesis
Precursor in the production of other chemical compounds
Used in medicinal chemistry to create new drug candidates
Solubility
Soluble in organic solvents like dichloromethane, ethyl acetate, and acetone
Insoluble in water
Stability
Stable under normal temperature and pressure
May decompose upon exposure to heat, light, or strong acids/bases
Reactivity
Can undergo various reactions due to the presence of multiple functional groups, such as substitution, addition, and esterification reactions
Synthesis
Can be synthesized through a multi-step process involving the formation of the indole ring, introduction of the substituents, and formation of the carboxylate groups
Hazards
May cause irritation to eyes, skin, and respiratory system
Toxicity data is limited, but should be handled with care and proper safety measures
Dispose of according to local regulations and guidelines
Check Digit Verification of cas no
The CAS Registry Mumber 937602-51-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,7,6,0 and 2 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 937602-51:
(8*9)+(7*3)+(6*7)+(5*6)+(4*0)+(3*2)+(2*5)+(1*1)=182
182 % 10 = 2
So 937602-51-2 is a valid CAS Registry Number.
937602-51-2Relevant articles and documents
INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
-
, (2019/09/30)
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
COMPOUNS, COMPOSITIONS AND METHODS OF USE
-
Page/Page column 232, (2018/07/29)
Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.
NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF
-
Paragraph 0760; 0761, (2018/09/08)
An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.
